Glesatinib
- Generic Name
- Glesatinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C31H27F2N5O3S2
- CAS Number
- 936694-12-1
- Unique Ingredient Identifier
- 7Q29OXD98N
- Indication
Investigated for use/treatment in cancer/tumors (unspecified).
- Associated Conditions
- -
- Associated Therapies
- -
Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2016-11-04
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 161
- Registration Number
- NCT02954991
- Locations
- 🇺🇸
Yuma Regional Medical Center, Yuma, Arizona, United States
🇺🇸USOR - Texas Oncology - Denison Cancer Center, Denison, Texas, United States
🇺🇸Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath